An Open-label, Multiple Dose Study to Assess the Steady-state Skin Concentrations and Pharmacokinetics of Vildagliptin 50 mg BID for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes.

Trial Profile

An Open-label, Multiple Dose Study to Assess the Steady-state Skin Concentrations and Pharmacokinetics of Vildagliptin 50 mg BID for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 11 Mar 2016

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 19 Dec 2008 Planned number of patients changed from 32 to 22 as reported by ClinicalTrials.gov.
    • 19 Dec 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 18 Dec 2008 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top